Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged equal or older than 18 years.~* Acute myocardial infarction (AMI) within 12 hours of evolution (from the onset of symptoms) systolic time elevation of at least 1 mm (recorded in two or more contiguous leads), new left bundle branch block, or true posterior infarction.~* Patients candidates for primary angioplasty as medical criteria~* Written informed consent according to International Conference on Harmonization / Guide Clinical Practice and local legislation, obtained before any study procedure.~* Diameter vascular coronary artery to treat between 2 mm and 4 mm.~* Patients with 85-100% stenosis and TIMI Score (Thrombolysis In Myocardial Infarction) of 0-I.~Exclusion Criteria:~* Patients who refuse to participate in the study~* Cardiogenic shock (defined as systolic blood pressure less than 80 mm Hg for more than 30 minutes or need for vasopressors or intra-aortic balloon counterpulsation)~* Concomitant diseases associated with a life expectancy of less than one year~* Angiographic variables:~  * Trunk unprotected~ * Branching (side branch greater than 2.5 mm)~ * Sinus tachycardia segment elevation myocardial infarction thrombosis secondary to stent~ * If more than one stent to treat a single segment (overlapping stents)~ * Patient candidate for surgical revascularization within 30 days~ * Stenosis of greater than 30 mm in length (corresponding with the ball longer available)~ * More severe stenosis in the same artery in which is expected to be addressed in the next 9 months~* Women at childbearing age, where there is the possibility of pregnancy during the first year of follow-up, or nursing.~* Any clinical condition, which in the opinion of the investigator, is considered clinically significant as to participate in the study.~* Subjects who are participating in any study drug or medical.~* Individuals who show inability to follow instructions or help during the course of the study.~* Bleeding diathesis or other disorders such as gastrointestinal ulceration or cerebral circulatory disorders, restricting the use of treatments platelet aggregation inhibitors and anticoagulants.~* Patients with an ejection fraction \<30% (if known).~* Allergy or hypersensitivity to paclitaxel intolerance, or compounds structurally related to the Butyryl tri-n-hexyl citrate (BTHC) matrix of administration.~* Severe allergy to contrast media.~* Coronary artery spasm in the absence of significant stenosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Bare metal Stent plus Paclitaxel Balloon (Type: EXPERIMENTAL): Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
- Drug-Eluting Stent (DES) (Type: ACTIVE_COMPARATOR): Sirolimus Eluting Stent (Orsiro®)

Based on this trial design, predict the completion outcome and termination type (if applicable).